Table 2 Clinicopathological factors with MGMT expression levels.
Clinicopathological factor (n = 142) | MGMT-positive (n = 97) | MGMT-negative (n = 45) | p value |
|---|---|---|---|
Clinical factor | |||
 Age, years, median (range) | 59 (18–79) | 56 (28–80) | 0.97 |
 Sex, male, n (%) | 47 (48) | 27 (57) | 0.2 |
Genetic syndrome, n (%) | |||
 MEN type 1 | 6 (6) | 4 (9) | 0.56 |
 VHL | 1 (1) | 1 (2) | 0.58 |
Tumor factor | |||
 Tumor size, mean ± SD, mm | 22.9 ± 24.6 | 42.1 ± 34.7 | 0.0015* |
 Ki-67 index, mean ± SD | 4.0 ± 6.5 | 7.5 ± 6.5 | 0.0035* |
 Mitosis, 10 HPF, mean ± SD | 1.2 ± 2.7 | 2.7 ± 4.1 | 0.036* |
 Lymph node metastasis, n (%) | 16 (16) | 8 (18) | 0.85 |
 Liver metastasis, n (%) | 22 (23) | 19 (42) | 0.017* |
 Chromogranin A positive, n (%) | 90 (93) | 41 (91) | 0.99 |
 Synaptophysin positive, n (%) | 95 (98) | 44 (98) | 0.99 |
 CD-56 positive, n (%) | 88 (91) | 43 (96) | 0.78 |
 Functionality, nonfunctioning, n (%) | 81 (84) | 40 (89) | 0.75 |
Tumor grade, n (%) | |||
 NET-G1 | 71 (73) | 9 (19) | < 0.001* |
 NET-G2 | 21 (22) | 35 (74) |  |
 NET-G3 | 5 (5) | 1 (2) |  |
